Newsroom | 1331 results

BEIJING--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it intends to file its definitive proxy materials in the coming days with the Securities and Exchange Commission (SEC) for the Special Meeting of Shareholders to be held on Wednesday, July 9, 2025 at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025 at 8:00 p.m. Atlantic Standard Time). Valid shareholders of record as of th...

PARIS--(BUSINESS WIRE)--SpikImm, a clinical-stage biotechnology company founded in 2021 by Truffle Capital in collaboration with Institut Pasteur and dedicated to the development of monoclonal antibodies to prevent viral infections in immunocompromised patients, today announced the signature with SATT Conectus of an exclusive collaboration and worldwide license agreement for potent monoclonal antibodies targeting the BK virus. These monoclonal antibodies were developed through the project HuMAB...

PARIS--(BUSINESS WIRE)--SpikImm, société de biotechnologie au stade clinique fondée en 2021 par Truffle Capital en collaboration avec l'Institut Pasteur et dédiée au développement d'anticorps monoclonaux pour prévenir les infections virales chez les patients immunodéprimés, annonce aujourd'hui la signature avec la SATT Conectus d'un accord exclusif de collaboration et d’un accord de licence mondiale pour des anticorps monoclonaux puissants ciblant le virus BK. Ces anticorps monoclonaux ont été...

UPPER NYACK, N.Y.--(BUSINESS WIRE)--Government vaccine committee house-cleaning puts chronically ill patients at risk as respiratory infection season looms...

OAKLAND, Calif.--(BUSINESS WIRE)--Long COVID claims represented only 4.7 percent of all California workers' comp COVID claims but 82 percent of COVID claim medical care payments....

SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies® and Quantoom Biosciences Sign License and Supply Agreement for CleanCap® mRNA Capping Technology...

LUXEMBOURG & LEIDEN, the Netherlands--(BUSINESS WIRE)--The European Investment Bank (EIB) and Dutch clinical-stage biotechnology company Leyden Laboratories B.V. have signed a €20 million financing deal to advance development of the Company’s broadly-protective antibodies to defend against seasonal and pandemic viral infections. Leyden Labs’ lead program is a pan-influenza nasal spray currently in clinical development (PanFlu), which has the potential to provide first-in-class influenza protect...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicine company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences: Jefferies Global Healthcare Conference (Presentation) Wednesday, June 4, 2025 (4:20 p.m. ET) Goldman Sachs Annual Global Healthcare Confere...

NORTH READING, Mass.--(BUSINESS WIRE)--Aphios has received a patent allowance for a single-dose, room temp-stable mRNA COVID-19 vaccine. No cold chain. No PEG. Just sustained protection....

DUBLIN--(BUSINESS WIRE)--The "Coronavirus (COVID-19) Current Therapy Market Opportunities and Strategies to 2034" report has been added to ResearchAndMarkets.com's offering. This report describes and explains the coronavirus (COVID-19) current therapy market and covers 2019-2024, termed the historic period, and 2024-2029, 2034F termed the forecast period. The report evaluates the market across each region and for the major economies within each region. The global coronavirus (COVID-19) current...